Eli Lilly's tirzepatide acts on two hormonal pathways, so it's called a dual GIP/GLP-1 receptor agonist, and it entered the ...

Let’s delve into the details of each of the evaluated factors, but first, for a quick background: With a $917 Bil market cap, ...

Apple became the first $1 trillion company on U.S. public markets in 2018. Six of the eight companies to follow in Apple’s ...

Philadelphia is the newest destination for Lilly Gateway Labs, an incubator for early-stage biotech companies backed by pharmaceutical giant Eli Lilly & Co., the company announced Wednesday. The ...

Even by dramatically lowering the prices of some of its medications, the drug giant is still outpacing its rivals and nearing ...

Eli Lilly stock has regained all-time highs, outpacing rivals in the obesity drug market. Click here to read my latest ...

South Korea’s newest billionaire is Lee Sang-hoon, founder of ABL Bio, after it struck a $2.6 billion licensing and joint ...

Lilly's tirzepatide is sold as Mounjaro for Type 2 diabetes and as Zepbound for weight loss -- but doctors have prescribed ...

Eli Lilly is poised to become the first $1 trillion pharmaceutical company, driven by explosive growth in its weight-loss ...

David Ricks' remarks followed a recent White House event where Trump announced his administration had reached a deal to lower ...

Eli Lilly CEO David Ricks said he prefers to use xAI's Grok and Anthropic's Claude over ChatGPT for science-related questions ...

Pharmaceutical giant Eli Lilly and Co. is bringing its next Gateway Labs to Philadelphia. Here's where and why.